Corrigendum to “ESPEN guideline: Clinical nutrition in inflammatory bowel disease” (Clinical Nutrition (2017) 36(2) (321–347), (S0261561416313681), (10.1016/j.clnu.2016.12.027))

Alastair Forbes; Johanna Escher; Xavier Hébuterne; Stanisław Kłęk; Zeljko Krznaric; Stéphane Schneider; Raanan Shamir; Kalina Stardelova; Nicolette Wierdsma; Anthony E. Wiskin; Stephan C. Bischoff

doi:10.1016/j.clnu.2019.01.017

Corrigendum to “ESPEN guideline: Clinical nutrition in inflammatory bowel disease” (Clinical Nutrition (2017) 36(2) (321–347), (S0261561416313681), (10.1016/j.clnu.2016.12.027))

Alastair Forbes^*, Johanna Escher, Xavier Hébuterne, Stanisław Kłęk, Zeljko Krznaric, Stéphane Schneider, Raanan Shamir, Kalina Stardelova, Nicolette Wierdsma, Anthony E. Wiskin, Stephan C. Bischoff

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Comment/debate

Abstract

The recommendations 14A, 32A, 33A, and 33B, which recommend “VSL#3 ^® ”, refer only to the product used in the cited literature and equivalent products independent from the present product labelings. This product is now known by the generic name “De Simone Formulation”. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	1486
Number of pages	1
Journal	Clinical Nutrition
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/j.clnu.2019.01.017
State	Published - Jun 2019

Access to Document

10.1016/j.clnu.2019.01.017

Cite this

Forbes, A., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S., Shamir, R., Stardelova, K., Wierdsma, N., Wiskin, A. E., & Bischoff, S. C. (2019). Corrigendum to “ESPEN guideline: Clinical nutrition in inflammatory bowel disease” (Clinical Nutrition (2017) 36(2) (321–347), (S0261561416313681), (10.1016/j.clnu.2016.12.027)). Clinical Nutrition, 38(3), 1486. https://doi.org/10.1016/j.clnu.2019.01.017

@article{95a407b97aba4bbbbb09af6a182e8ff6,

title = "Corrigendum to “ESPEN guideline: Clinical nutrition in inflammatory bowel disease” (Clinical Nutrition (2017) 36(2) (321–347), (S0261561416313681), (10.1016/j.clnu.2016.12.027))",

abstract = " The recommendations 14A, 32A, 33A, and 33B, which recommend “VSL#3 {\textregistered} ”, refer only to the product used in the cited literature and equivalent products independent from the present product labelings. This product is now known by the generic name “De Simone Formulation”. The authors would like to apologise for any inconvenience caused.",

author = "Alastair Forbes and Johanna Escher and Xavier H{\'e}buterne and Stanis{\l}aw K{\l}{\c e}k and Zeljko Krznaric and St{\'e}phane Schneider and Raanan Shamir and Kalina Stardelova and Nicolette Wierdsma and Wiskin, {Anthony E.} and Bischoff, {Stephan C.}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = jun,

doi = "10.1016/j.clnu.2019.01.017",

language = "אנגלית",

volume = "38",

pages = "1486",

journal = "Clinical Nutrition",

issn = "0261-5614",

publisher = "Churchill Livingstone",

number = "3",

}

Forbes, A, Escher, J, Hébuterne, X, Kłęk, S, Krznaric, Z, Schneider, S, Shamir, R, Stardelova, K, Wierdsma, N, Wiskin, AE & Bischoff, SC 2019, 'Corrigendum to “ESPEN guideline: Clinical nutrition in inflammatory bowel disease” (Clinical Nutrition (2017) 36(2) (321–347), (S0261561416313681), (10.1016/j.clnu.2016.12.027))', Clinical Nutrition, vol. 38, no. 3, pp. 1486. https://doi.org/10.1016/j.clnu.2019.01.017

TY - JOUR

T1 - Corrigendum to “ESPEN guideline

T2 - Clinical nutrition in inflammatory bowel disease” (Clinical Nutrition (2017) 36(2) (321–347), (S0261561416313681), (10.1016/j.clnu.2016.12.027))

AU - Forbes, Alastair

AU - Escher, Johanna

AU - Hébuterne, Xavier

AU - Kłęk, Stanisław

AU - Krznaric, Zeljko

AU - Schneider, Stéphane

AU - Shamir, Raanan

AU - Stardelova, Kalina

AU - Wierdsma, Nicolette

AU - Wiskin, Anthony E.

AU - Bischoff, Stephan C.

PY - 2019/6

Y1 - 2019/6

N2 - The recommendations 14A, 32A, 33A, and 33B, which recommend “VSL#3 ® ”, refer only to the product used in the cited literature and equivalent products independent from the present product labelings. This product is now known by the generic name “De Simone Formulation”. The authors would like to apologise for any inconvenience caused.

AB - The recommendations 14A, 32A, 33A, and 33B, which recommend “VSL#3 ® ”, refer only to the product used in the cited literature and equivalent products independent from the present product labelings. This product is now known by the generic name “De Simone Formulation”. The authors would like to apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85060529794&partnerID=8YFLogxK

U2 - 10.1016/j.clnu.2019.01.017

DO - 10.1016/j.clnu.2019.01.017

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 30704889

AN - SCOPUS:85060529794

SN - 0261-5614

VL - 38

SP - 1486

JO - Clinical Nutrition

JF - Clinical Nutrition

IS - 3

ER -

Corrigendum to “ESPEN guideline: Clinical nutrition in inflammatory bowel disease” (Clinical Nutrition (2017) 36(2) (321–347), (S0261561416313681), (10.1016/j.clnu.2016.12.027))

Abstract

Access to Document

Other files and links

Fingerprint

Cite this